Recent work from the Osmani laboratory [5] now brings NIMA into the Cdc2 paradigm, by suggesting that the two pathways may converge after all, with NIMA possibly being a substrate of the Cdc2 kinase. The updated model places NIMA downstream of Cdc2. Specifically, it is proposed that NIMA activation requires two steps (Fig. la) . In the first, NIMA is phosphorylated either through autophosphorylation or by an as yet unidentified kinase; in the second, it is further phosphorylated by Cdc2, presumably on one or several of the seven putative Cdc2 target sites identified in its carboxy-terminal non-catalytic domain (Fig. c) . The first, Cdc2-independent phosphorylation step generates a protein that is at least partially active [6] , and the second, Cdc2-dependent, phosphorylation leads to further activation of NIMA [5] . This model raises new questions as to the exact nature of the dependency of the two enzymes on each other. In particular, it will be important to determine to what extent Cdc2 acts through NIMA and, conversely, whether partially activated NIMA can act on its substrates before being hyperphosphorylated by Cdc2. Also, it remains to be examined whether or not Cdc2 phosphorylates NIMA directly in vivo or operates through an intermediate kinase, and whether this phosphorylation modulates only the kinase activity of NIMA or also influences its subcellular localization or stability.
It is interesting to compare the effects of overexpressing either the Cdc2 or the NIMA kinase. Massive overexpression of NIMA was reported to lead to mitotic induction in Aspergillus, regardless of the cell's position in the cell cycle, suggesting that the proposed hyperphosphorylation of NIMA by Cdc2 is not necessary in this experimental setting [7] . Conversely, dominant-negative mutants of NIMA induced a G2-phase arrest in HeLa cells [8] , but this arrest could be overcome by a constitutively active Cdc2 mutant [9] . Interpretation of overexpression experiments is difficult, however, and the above results may not reflect the interdependence of the pathways under physiological conditions. In particular, NIMA appears to be present at very low abundance in vivo [6, 10] , and stimulation by Cdc2 phosphorylation may be required to generate NIMA activities approaching the levels obtained through overexpression. Thus, although overexpression of either one of the two kinases appears to be able to promote certain aspects of mitosis, the recent work in Aspergillus would suggest that, under physiological conditions, NIMA and Cdc2 may act in concert.
A role for NIMA in chromatin condensation? Two studies have now shown that NIMA overexpression can cause chromatin condensation, not only in Aspergillus but also in fission yeast, Xenopus oocytes and human cells [9, 10] . It will be important to determine by what mechanism(s) elevated NIMA activity causes chromatin condensation, and the precise relationship of the observed phenomena to bona fide mitotic events remains to be defined. In particular, there were no signs of mitotic spindle formation in Xenopus, yeast or human cells (a) A model in which activation of both NIMA and the Cdc2-cyclin B complex is necessary to allow cells to enter mitosis. Activation of Cdc2-cyclin B occurs through dephosphorylation of critical sites by the Cdc25 phosphatase; activation of NIMA is proposed to occur by two steps of phosphorylation, the second of which seems to be dependent on active Cdc2, providing a point of convergence for the two pathways. (b) Exit from mitosis into G1 requires inactivation of the two kinases, probably as a result of degradation of NIMA and cyclin B. Cyclin B is degraded at about the metaphase-to-anaphase transition, but NIMA protein disappears later. Cyclin destruction is regulated by poly-ubiquitination, but the disappearance of NIMA remains to be explained, and might result principally from a transient arrest in synthesis. (c) Sequence analysis and experiments with nimA mutants have revealed several distinct domains within the NIMA protein.
expressing elevated levels of NIMA kinase activity [9, 10] . In HeLa cells and Xenopus oocytes, NIMA-induced chromatin condensation was accompanied by nuclear envelope breakdown and disappearance of the nuclear lamina [9] . However, no biochemical studies have been performed to determine whether the nuclear lamina was depolymerized through phosphorylation, which would be indicative of a mitotic event, or degraded through proteolysis, indicative of apoptosis [10] . Thus, at this stage, chromatin condensation is the only process reproducibly associated with NIMA overexpression.
The carboxyl terminus of NIMA is rich in regulatory motifs
NIMA is a 79 kDa protein with a serine/threoninespecific kinase domain at the amino terminus and a carboxy-terminal domain that has been shown to confer multiple levels of regulation on the kinase (Fig. c) . As mentioned above, phosphorylation of the putative p34cdc 2 sites contained within this region is likely to explain the mitotic hyperphosphorylation and maximal activation of NIMA. Structural motifs in the carboxyl terminus also account, at least in part, for the observed cell-cycledependent expression of NIMA; the kinase activity of NIMA is low in G1 but increases through S and G2 to reach maximal levels in mitosis [6] . Furthermore, the NIMA protein was shown to accumulate when cells were arrested in G2, but to disappear as they traversed mitosis [5] . Two groups have shown independently that large truncations of the carboxy-terminal domain stabilize the NIMA protein [10, 11] . These truncations remove not only the putative Cdc2 phosphorylation sites but also several 'PEST' sequences (rich in proline, glutamic acid, serine and threonine), which may be responsible for conferring a short half-life on the wild-type protein (Fig.  1c) . The accumulation of stable truncated mutant NIMA proteins led to a mitotic arrest in Aspergillus, indicating that reducing the level of NIMA is necessary for exit from mitosis [11] . This is reminiscent of the situation for cyclin B, which is expressed in a similar cell-cycle-dependent manner and causes a mitotic arrest when expressed as a non-destructible mutant. Interestingly, the mitotic arrest induced by stable NIMA proteins occurred despite the normal proteolysis of cyclin B. It is possible, but remains to be proven, that NIMA may be part of a growing family of proteins that need to be destroyed, in addition to cyclin B, in order for cells to exit mitosis (Fig. lb) .
Expression of the carboxy-terminal domain of NIMA by itself produces a dominant-negative phenotype, inducing a G2 arrest in both Aspergillus and HeLa cells [8, 9] . Deletion studies have revealed a specific stretch of approximately 100 amino acids at the beginning of the carboxy-terminal domain which is required for the nuclear localization of NIMA and necessary for the dominant-negative G2 arrest phenotype [9] . This sequence shows significant homology to coiled-coil domains and might be important for targeting NIMA to substrates or to specific subcellular compartments through protein-protein interactions (Fig. c) . Thus, the carboxyterminal domain of NIMA appears to control the activation, stability and localization of the kinase, thereby performing very similar functions to those attributed to the cyclin moiety within the p34,dc2-cyclin B complex.
Identification of Neks, mammalian NIMA-related kinases
As described above, overexpression of NIMA leads to premature chromatin condensation in a wide range of eukaryotic cells. Additional evidence that NIMA pathways exist in higher eukaryotes has come from the demonstration that dominant-negative mutants of nimA can induce a dose-dependent G2 arrest in HeLa cells [9] . Taken together, these results provide good reasons to predict that homologues of nimA are likely to be found in other organisms, including metazoans. The only species for which a genuine functional homologue of nimA has so far been identified is another filamentous fungus, Neurospora crassa [12] , but genes encoding protein kinases structurally related to NIMA have been cloned from yeast and trypanosomes, as well as from higher eukaryotes. In particular, several full-length or partial Nek (NIMA-related kinase) cDNAs have been isolated in mammals [9, [13] [14] [15] suggesting the existence of a whole family of NIMA-related kinases. By analogy to the various CDK-cyclin complexes, different Nek family members may function during different phases of the cell cycle or in different tissues.
At present, the best characterized of these proteins is the human Nek2. Of all NIMA-related kinases, Nek2 shares the greatest sequence similarity with NIMA, being 47 % identical over the catalytic domain [15] . Moreover, despite a lack of sequence conservation beyond the catalytic domain, Nek2 also contains a coiled-coil motif at the beginning of its carboxy-terminal domain (A.E and E.N., unpublished observations). In addition, the substrate specificity in vitro and biochemical properties of Nek2 are reminiscent of NIMA [16] , and Nek2 protein levels and activity are regulated through the cell cycle [15, 16] . But significant differences do exist between NIMA and Nek2: most notably, whereas NIMA activity peaks in mitosis [6] , Nek2 activity peaks in S/G2 phase and is low when cells are in mitosis [16] . Also, Nek2 contains none of the putative Cdc2 phosphorylation sites or PEST motifs identified in the carboxyl terminus of NIMA. These data suggest that Nek2 might function earlier in the cell cycle than NIMA, and perhaps another Nek family member is required to perform the purported mitotic function of NIMA. Indeed, overexpression of Nek2 does not appear to lead to any detectable mitotic phenotype (A.E and E.N., unpublished results, and [9] ). On the other hand, it should be kept in mind that Aspergillus has a 'closed' mitosis, in which the nuclear envelope does not break down; hence, the regulation of mammalian NIMA homologues in both time and space may be different from the situation in Aspergillus.
In conclusion, there are now good indications that NIMA pathways may exist beyond Aspergillus. Several candidate vertebrate homologues of NIMA have already been identified, but others may remain to be found. At this stage, it is important to determine in what capacity Nek2 and its fellow family members contribute to cellcycle regulation in vertebrate cells, and how they interact with the ever-growing panoply of CDK-cyclin complexes. The latest studies with the Aspergillus NIMA protein discussed here have provided sufficient clues to make those working in this field confident that they will soon move closer to the mainstream of cell-cycle research.
